Encore at Wynn
Las Vegas, Nevada
Friday, September 14, 2018 | 6:15PM-7:15PM
Will be available directly following the activity.
Daniel E. Furst, MD
Professor of Rheumatology,
University of Washington School
David Geffen School of
Medicine at UCLA
Los Angeles, California
Division of Allergy, Immunology,
University of Rochester
Rochester, New York
ACTIVITY AND CME INFORMATION
The target audience is rheumatologists and nurse practitioners and physician assistants who specialize in rheumatology. Other clinicians who treat patients with PsA may benefit from participation in this educational activity.
Steps Ahead: Emerging Therapies in Psoriatic Arthritis is a fast-paced workshop featuring real-life scenarios and discussions designed to provide new ideas, answers, and confidence in treating PsA. Through a series of presentations and exercises, attendees will cover a range of diagnosis and therapeutic options, opportunities, and outcomes to ultimately gain a deeper understanding on how to better address care gaps and move the treatment of PsA forward.
As a result of participation in this educational activity, participants should increase their ability to:
Optimize monitoring for adherence to treatment, achievement of treatment targets, adverse events, and comorbidities in patients with PsA.
Translate evidence-based recommendations and the latest research data related to use of DMARDs in PsA into clinically meaningful information for managing patients with PsA.
Develop a patient-centered approach to coordination of PsA care between rheumatology and dermatology providers.
Effectively engage patients with PsA in SDM regarding treatment goals, development of the treatment plan, and treatment modification.
CREDIT DESIGNATION STATEMENT
Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.2 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.
This activity is approved for 1.00 contact hour(s) of continuing education (which includes .50 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 18083318. This activity was planned in accordance with AANP CE Standards and Policies.
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the online resources.
6:15 pm - 7:15 pm
Welcome and Session Overview
Applying GRAPPA and ACR/NPF Recommendations
to Treatment of PsA in Routine Clinical Practice
Daniel E. Furst, MD
Patient-Centered Care for Patients With Psoriasis and PsA
Linda Grinnell-Merrick, MS, NP-BC
Feedback & Discussion
Question and Answer Session
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.
This symposium is independently organized and not an official part of The 11th Perspectives in Rheumatic Diseases conference.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Forefront Collaborative complies with the Americans with Disabilities Act and will make every reasonable effort to accommodate your request. For special requests, please call Christine Tebben at 317.208.2768 prior to this activity.